NICE
NICE rejects Otelza but SMC recommends it
June 11, 2015Sales and Marketing Astellas, Celgene, NHS, NICE, SMC, Xtandi, otezla
Draft guidance issued by NICE has seen rejections for products including Celgene’s Otelza and Astellas Pharma’s Xtandi, and a call …
NICE issues guidance for two prostate cancer drugs
June 5, 2015Sales and Marketing Bayer, Ferring, NICE, firmagon, xofigo
NICE has published draft guidance for two prostate cancer drugs, recommending a Bayer medicine but rejecting one from Ferring Pharmaceuticals. …
NICE U-turn on Janssen arthritis drug
June 4, 2015Sales and Marketing Janssen, NICE, Stelara, psoriasis, uturn
NICE has performed a U-turn on Janssen’s Stelara and has now recommended the drug for the treatment of psoriatic arthritis. …
NICE: people should be more involved in medical decisions
June 2, 2015Sales and Marketing NHS, NICE, medicines, optimisation
Around 15 million people in England now have at least one long-term condition, but figures suggest that as many as …
NICE signs-off Roche’s Gazyvaro for leukaemia
June 2, 2015Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia
NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …
NICE Lynparza rejection labelled ‘hard to understand’
June 2, 2015Sales and Marketing AstraZeneca, NICE, lynparza, olaparib
AstraZeneca has appealed to the government to put ‘urgent transitional measures’ in place to make sure patients can access innovative …
NICE green-light for Novartis skin drug
May 29, 2015Sales and Marketing Cosentyx, IL-17, NICE, Novartis, Secukinumab
NICE has released positive draft guidance for three treatments, including the first in a new generation of psoriasis drugs. Novartis’ …
NICE sets out office for market access plans
May 28, 2015Sales and Marketing ABPI, EMA, NHS, NICE, eams, market access
The UK healthcare watchdog NICE is to set up a new office for market access to advise pharma companies on …
Pharma accused of hiding behind regulation and undermining NICE
April 29, 2015Medical Communications, Sales and Marketing NHS, NICE, Royal Society of Medicine, UK, brett wells, health, pharma
University of York health economists have argued that pharma regulation is not evidence-based, lacks accountability and undermines NICE. Writing in …
BMS lifted by new products
April 28, 2015Sales and Marketing BMS, NICE, Q1, eams, immuno-oncology and hepatitis C
New drugs have helped Bristol-Myers Squibb see a slight increase in sales for the first quarter of 2015. Total revenues …
Novartis heart drug steps closer to EAMS scheme
April 23, 2015Sales and Marketing LCZ696, MHRA, Medicines and Healthcare products Regulatory Agency, NICE, eams, pim, sacubitril/valsartan
Novartis’ investigational heart failure drug LCZ696 has been handed a Promising Innovative Medicine designation (PIM) after showing that it significantly …
FDA approves Amgen’s heart failure drug
April 16, 2015Sales and Marketing Amgen, Corlanor, FDA, NICE, Vectibix, heart, ivabradine
Amgen has earned sign-off from the FDA for Corlanor as a treatment for people with worsening heart failure symptoms. Corlanor …
Trial results back NICE decision on Novartis cancer drug
April 15, 2015Sales and Marketing Arzerra, Cancer, NHS, NICE, chemo, chlorambucil, fludarabine, leukaemia, ofatumumab
Treatment with Arzerra improves survival in people with chronic lymphocytic leukaemia (CLL) according to study results that back NICE’s decision …
Refining UK market access
April 7, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, UK, health, market access
“Some people have said NICE needs to change, it needs to create a new vision, but we say we need …
NICE names new non-executive director
March 25, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, tim irish
The Department of Health has appointed Tim Irish as a non-executive director of the National Institute for Health and Care …
Latest content
FibroFind appoints Lee Borthwick as CEO
